Trovagene raises $7m for precision cancer therapies

Trovagene (NSDQ:TROV) said today that it inked a deal with unnamed investors to sell approximately $7.1 million of its common stock. According to the deal, Trovagene plans to sell 6,191,500 shares of common stock. In a concurrent private placement, the biotech said it will issue warrants to buy up to 4,643,626 shares of common stock. Get the full story at our sister site, Drug Delivery Business News. The post Trovagene raises $7m for precision cancer therapies appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Diagnostics Funding Roundup Oncology Pharmaceuticals Wall Street Beat Trovagene Source Type: news

Related Links:

Publication date: Available online 16 October 2018Source: International Journal of PharmaceuticsAuthor(s): Kensuke Yotsumoto, Kenta Ishii, Miho Kokubo, Sakiko YasuokaAbstractPolymeric micelles, which form through the self-assembly of poly(ethylene glycol)–poly(amino acid) block copolymers, are systemic nanocarriers in targeted cancer therapy. These micelles can encapsulate therapeutic compounds, such as lipophilic substances, charged compounds, and metal complexes, that have characteristics of increased solubility, sustained release, and improved tissue distribution. However, few studies have been conducted on the lo...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies. Get the full story at our sister site, Drug Delivery Business News. The post Nanobiotix reels in $18.5m tranche from European Investment Bank appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Funding Roundup Oncology Pharmaceuticals Wall Street Beat nanobiotix Source Type: news
In this study, we have further investigated the anti-tumor effects of D5D-knockdown and the resulting intensified COX-2-catalyzed DGLA peroxidation in subcutaneous xenograft tumors. Four-week old female nude mice (Jackson Laboratory, J:Nu-007850) were injected with human pancreatic cancer cell line BxPC-3 or its D5D knockdown counterpart (via shRNA), followed by 4-week treatments of: vehicle control, DGLA supplementation (8 mg/mouse, twice a week), gemcitabine (30 mg/kg, twice a week), and a combination of DGLA and gemcitabine. In D5D-knockdown tumors, DGLA supplementation promoted 8-HOA formation to a threshold ...
Source: Redox Biology - Category: Biology Source Type: research
Publication date: 15 February 2019Source: Chemical Engineering Journal, Volume 358Author(s): Wei Zhu, Li Zhang, Zhe Yang, Pei Liu, Jing Wang, Jinguo Cao, Aiguo Shen, Zushun Xu, Jing WangAbstractThough imaging guided photodynamic therapy (PDT) has emerged as a promising cancer therapy, how to enhance the PDT efficiency is still a research hotpot due to the tumor hypoxia and insufficient dosage of photosensitizers in the tumor site. Herein, a multifunctional theranostic nanoplatform was rationally constructed by nanoscale metal organic frameworks (NMOFs), bovine serum albumin (BSA), sulfadiazines (SDs), and MnO2. Porphyrin a...
Source: Chemical Engineering Journal - Category: Chemistry Source Type: research
AbstractPurpose of ReviewAs the modern era of cancer treatment improves survival for patients, intensive care units (ICUs) play an increasing role in their management to support patients during cancer therapy. This review seeks to summarise some important changes and persisting challenges in the care of this complex patient group.Recent FindingsTechnological advances and improvements in overall cancer treatment have challenged historical approaches to suitability for admission and provision of ICU support. In particular, old paradigms (such as not admitting hematological malignancy patients to the ICU for mechanical ventil...
Source: Current Anesthesiology Reports - Category: Anesthesiology Source Type: research
Immunotherapy,Volume 10, Issue 14, Page 1265-1284, October 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
AbstractPurposeThis observational study was designed to measure baseline energy parameters and body composition in early-stage breast cancer patients, and to follow changes during and after various modalities of treatment. This will provide information to aid in the development of individualized physical activity intervention strategies.MethodsPatients with newly diagnosed stage 0 –III breast cancer were enrolled into three cohorts: A (local therapy alone), B (endocrine therapy), or C (chemotherapy with or without endocrine therapy). At baseline, 6 months, and 12 months, subjects underwent a stationary bicy...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The combination of phytochemicals with chemotherapy drugs is an emerging new strategy for cancer therapy to increase antitumor responses.
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Funding